We also evaluated the prognostic roles of FAT1 mutations in melanoma and NSCLC patients treated with distinct chemotherapies from TCGA cohorts; and no significant survival differences were observed between FAT1 mutated and wild-type subgroups in both tumors (Log-rank test, both P > 0.05; Supplementary Fig. 9). The gene discussed is FAT1; the disease is melanoma.